Cardio Diagnostics Holdings, Inc.

NasdaqCM CDIO

Cardio Diagnostics Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -6.09 M

Cardio Diagnostics Holdings, Inc. Free Cash Flow is USD -6.09 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 16.98% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Cardio Diagnostics Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -7.34 M, a -213.56% change year over year.
Cardio Diagnostics Holdings, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.34 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: CDIO

Cardio Diagnostics Holdings, Inc.

CEO	Dr. Meeshanthini V. Dogan Ph.D.
IPO Date	Jan. 14, 2022
Location	United States
Headquarters	400 N Aberdeen St
Employees	7
Sector	Health Care
Industries Clinical Trials Biotechnology

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Key trends

Past 5 years